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Summary
Wehave extended the search for selective inhibitors of
the kinases of MAPK cascades by screening a deriva-
tive library of one of the isoquinoline rings of the
protoberberine backbone. HWY 5069 inhibited the pro-
liferation of wild-type and all mutants of Schizosac-
charomyces pombe examined, except spc1D, at amin-
imal inhibitory concentration (MIC) of 3.76 mM. HWY
5069 also completely inhibited Spc1 kinase activity
in vitro with an IC50 of 16.4 mM as a competitive inhib-
itor of substrate binding. It was highly selective for
Spc1 and did not affect the activity of other kinases
in the MAPK cascades of fission yeast and mammals,
including functional homologs of Spc1.
Introduction
MAPK cascades are highly conserved signaling cas-
settes activated by diverse extracellular stimuli that reg-
ulate proliferation, differentiation, inflammation, and cell
death in eukaryotes. Therefore, inhibitors of the kinases
of particular MAPK cascades are candidates for cyto-
toxic antifungal, antitumor, or anti-inflammatory drugs.
Each MAPK cascade consists of a series of three or
more protein kinases, each of which phosphorylates
and activates the next kinase in the pathway. MAPK ki-
nases (MAPKK, MKK, or MEK) are activated by MAPKK
kinases (MAPKKK or MEKK) and, in turn, activate
MAPKs by phosphorylating them on conserved serine/
threonine and tyrosine residues of their catalytic do-
mains. Several MAPK cascades exist in parallel within
a cell, each transducing a specific signal. In addition, in-
dividual MAPK pathways often interact with each other
and form a complex network [1–3]. Analysis of the mech-
anisms underlying MAPK signaling specificity in mam-
malian cells has been greatly aided by the development
of synthetic compounds that inhibit particular com-
ponents of the cascades: PD98059 (2-[20-amino-30-
methoxyphenyl]-oxanaphthalen-4-one) against MEK1,
U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophe-
nylthio]-butadiene) against MEK1 and MEK2, the pyri-
dinyl imidazoles SB203580 (4-[4-fluorophenyl]-2-[4-
*Correspondence: bc5012@yonsei.ac.kr
3 These authors contributed equally to this work.methylsulfonylphenyl]-5-[4-pyridyl]-1H-imidazole) and
SB202190 (4-[4-fluorophenyl]-2-[4-hydroxyphenyl]-
5-[4-pyridyl]1H-imidazole) against stress-activated pro-
tein kinases (SAPK) 2a and 2b as well as p38 MAPK
isoforms, and the anthrapyrazolone SP600125 (anthra
[1,9-cd]pyrazol-6[2H]-one) against c-Jun N-terminal
protein kinase (JNK) [4–9].
The fission yeast Schizosaccharomyces pombe is
useful for screening inhibitors of the kinases in MAPK
cascades due to the high degree of conservation and
relative simplicity of its MAPK cascades. Three MAPK
cascades have been identified in S. pombe. The MAPK
Spk1, the MAPKK Byr1, the MAPKKK Byr2, and the
small GTPase Ras1 comprise a cascade required for
mating and sporulation [10–12]. The Wis1-Spc1 path-
way, which is required for survival under various stress
conditions, such as high osmolarity and oxidative
stress, involves the MAPKKKs Win1 and Wis4, the
MAPKK Wis1, and the MAPK Spc1 [13–15]. The third
stress-activated MAP kinase cascade consists of the
MAPKKK Mkh1, the MAPKK Skh1, and the MAPK
Spm1 and regulates morphogenesis and cell wall integ-
rity in response to environmental conditions [16–18]. The
Wis1-Spc1 pathway bears many functional similarities
to the MKK4/7-JNK/SAPK and MKK3/6-p38 pathways
of mammals [15, 19], and the Ras1-Byr2-Byr1-Spk1
pathway shows similarities with the mammalian Ras-
Raf-MEK1-ERK pathway [19].
The binding target molecule(s) of a known chemical
compound can be identified by comparing its effect on
wild-type cells and mutants lacking genes for the target.
Such approaches with the budding yeast Saccharomy-
ces cerevisiae have provided invaluable insights into
the actions of a number of drugs and compounds with
specific effects on both mammals and fungi [20, 21].
For example, the binding targets of rapamycin, cyclo-
sporin, and FK 506 for cell cycle arrest were first identified
inS. cerevisiae [22–26], and selective inhibitors of protein
kinases, such as Cdc28, were also isolated by screening
S. cerevisiae mutants with the libraries of trisubstituted
purine analogs [20, 27]. Similarly, by screening a variety
of fission yeast S. pombe mutants, we previously re-
ported that Wis1 was the intracellular binding target of
a novel, to our knowledge, berberine derivative [28].
In this study, we extended our search for selective in-
hibitors of the kinases of MAPK cascades by extensively
modifying one of the two isoquinoline rings on the pro-
toberberine backbone by using a variety of S. pombe
mutants.
Results
Screening Isoquinolinium Derivatives and
Identifying Their Targets
We generated a privileged small-scale chemical library
by modifying one of the two isoquinoline rings of proto-
berberine as shown in Figure 1A, and we screened 80
derivatives for decreased toxicity on strains with dele-
tions of specific kinases in the MAPK cascades com-
pared with wild-type so as to isolate the chemicals
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(A) A privileged chemical library of isoquino-
linum derivatives was synthesized by modifi-
cation of one of the two isoquinoline rings of
the protoberberine backbone. In the reac-
tion, R1 represents hydrogen, the C1–C12 al-
kyl, or the C3–C12 alkenyl; R2 represents
benzyl with optionally substituted Z1, Z2,
Z3, Z4, and Z5, which may be the same or
different, as well as hydrogen, halogen, the
C1–C5 alkoxy, or trifluoromethoxy; R3 and
R4 may be the same or different, and they
represent hydrogen, halogen, methylene-
dioxy, or the C1–C10 alkyloxy. X represents
an inorganic acid ion, an organic acid ion,
or a halide.
(B) The scheme used to synthesize a novel,
to our knowledge, isoquinolinium derivative,
HWY 5069, from a phenylethylamine deriva-
tive; 3-fluorophenylethylamine (1) (Sigma)
was acylated with a long-chain acid chloride to give amide (2). The amide (2) was subsequently treated with phosphorus oxychloride to
give isoquinoline (3), which was further reacted with t-butylbenzyl bromide to provide the desired isoquinolinium salt (4) as a yellow solid.
The structures of the final product and intermediates were confirmed by 1H NMR (300 MHz, CDCl3),
13C NMR (75 MHz, CDCl3), and HR-MS
spectroscopy.that use the kinases in the MAPK cascades as their bind-
ing targets. Previously, the FK 506 binding protein
(FKBP), proline rotamase, was first identified as the
in vivo binding target of the immunosuppressant FK 506
by demonstrating that wild-type yeast is sensitive to
FK 506, but that an S. cerevisiae mutant lacking proline
rotamase (FPR1) was neither lethal nor resistant to FK
506 [23]. It was shown later that FK 506 forms a complex
with the highly conserved FKBP12, which, in turn, spe-
cifically targets calcineurin, the Ca2+-calmodulin-regu-
lated serine/threonine-specific protein phosphatase,
and induces decreased proliferation [29]. The difference
in the sensitivity to FK 506 of wild-type cells and those
with a deletion of its target is explained by the notion
that FK 506 and the target complex recruit another phys-
iologically critical molecule required for viability. We
used a similar rationale to screen for selective inhibitors
of the kinases in the MAPK pathways (Figure 2) of S.
pombe, in which deletion mutants of each of the kinases
in the MAPK cascades are viable.We first examined the cytotoxic effects of the newly
synthesized, to our knowledge, isoquinolinium deriva-
tives on wild-type fission yeast. HWY 5069 was found
to completely inhibit the growth of wild-type S. pombe,
whereas solvent (DMSO)-only-treated cells showed no
effect (Figure 3A). The minimal inhibitory concentration
(MIC) of HWY 5069 was 3.76 mM. This inhibitory effect
of HWY 5069 on cell proliferation was reversible since
wild-type HWY 5069-treated cells resumed active prolif-
eration after several washes (Figure 3B).
We then examined the sensitivity of various kinase
mutants to HWY 5069. HWY 5069, at the MIC of the
wild-type, inhibited the proliferation of all of the S.
pombemutants tested, except the spc1 deletion mutant
(Figure 3C), while all of these tested mutants showed
similar growth rates in the absence of HWY 5069
(Figure 3D). The effect of HWY 5069 on temperature-
sensitive S. pombe Cdc2 and Plo1 was also examined.
These mutants were as sensitive to HWY 5069 at their
restrictive temperatures as wild-type (data not shown).Figure 2. Rationale of the Genetic Approach to Identify the Binding Target of a Privileged Library of Isoquinolinium Derivatives
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(A) The effect of HWY 5069 on the proliferation of wild-type S. pombe (KGY246). The same number of wild-type cells in early-log phase was
incubated for 24 hr with 3.76 mM HWY 5069 and DMSO (solvent) as a negative control.
(B) Reversibility of the effect of HWY 5069 on the growth of wild-type S. pombe. After incubation with 3.76 mM HWY 5069 for 18 hr, the cells
were washed three times, transferred to drug-free medium, and counted 6 and 12 hr later. The arrow indicates the removal of HWY 5069
by wash.
(C) The ability of 3.76 mM HWY 5069 to inhibit the growth of the wild-type (KGY 246) and various S. pombe mutants with deletions of each
component in the MAPK pathways was examined as in (A).
(D) The same mutants as in (C) were only treated with solvent to show their similar growth rates in the absence of HWY 5069.
All experiments were performed three times, and averages with standard deviations are plotted.These observations show that the binding target of HWY
5069 is the stress-activated MAPK Spc1, and that it has
no effect on the immediate upstream regulators of Spc1
(Wis1, Win1, and Wis4) or on other MAPKs.
Selective Inhibition of Spc1 Kinase by HWY 5069
The lack of sensitivity of the spc1 mutant to HWY 5069
led us to examine whether HWY 5069 directly binds
to and inhibits Spc1 kinase activity. We generated
KGY246 cells expressing 6XHis/HA-tagged Win1, Skh1,
Spm1, or Byr1 and GST-tagged Wis1 or Spc1 protein.
Each kinase was then purified with tag-specific beads
or antibodies and examined for sensitivity to HWY 5069
(see Experimental Procedures). HWY 5069 completely
blocked Spc1 kinase activity, whereas the lead com-
pound, berberine chloride, had no effect (Figure 4A).
The IC50 of HWY 5069 for Spc1 inhibition was 16.4 mM
(Figure 4B). However, HWY 5069 had no effect on Win1
and Wis1, which operate upstream of Spc1 (Figure 4C),
nor did it affect the kinases of other S. pombe MAPK
cascades, namely, Skh1, Byr1, and Spm1, even at250 mM (Figure 4C and data not shown). These obser-
vations are consistent with the results in Figures 3A
and 3C, and they prove that HWY 5069 only inhibits Spc1.
In order to determine that HWY 5069 exclusively
blocks the kinase activity of Spc1 on its physiological
substrate as well as the general substrate for kinase as-
says, MBP, we examined whether HWY 5069 is able to
inhibit the autophosphorylation of Spc1. Both Spc1 and
Wis1 are known to autophosphorylate themselves to
amplify the activation of their signaling cascade [30, 31].
The autophosphorylation activity of affinity-purified
Spc1 was assayed after it was preincubated with 10,
25, 100, and 250 mM HWY 5069 (Figure 4D). The effect
of HWY 5069 on Spc1 autophosphorylation activity was
also compared with its effect on the autophosphorylation
activity of Wis1 as a negative control. As expected from
the observation that HWY 5069 specifically blocks Spc1
kinase activity by using MBP as a substrate, HWY 5069
selectively inhibited the autophosphorylating kinase
activity of Spc1 as well in a concentration-dependent
manner, while it did not affect the autophosphorylating
Chemistry & Biology
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Spc1 MAPK In Vitro
(A) The inhibition of Spc1 kinase activity by
HWY 5069. The kinase activity of purified
Spc1 was tested with MBP as a substrate af-
ter incubation with 25 mM HWY 5069 (left) or
200 mM berberine, the lead compound, as
a negative control (right). Phosphorylated
MBP was detected by autoradiography. A
similar amount of substrate was used in
each kinase assay, as shown by the Coo-
massie-stained MBP (right).
(B) The concentration-dependent inhibition
of Spc1 by HWY 5069. A similar amount of
Spc1 was used in each assay, as shown by
a Western blot at the bottom. DMSO (lane
1) and berberine chloride (200 mM, lane 2)
served as negative controls. The experiment
was performed three times, and phosphory-
lated MBP was quantified with a Phosphor-
Imager. Average activities relative to the
DMSO control are shown in the histogram
as percentages with standard deviations.
(C) The effect of HWY 5069 on the kinase ac-
tivity of Win1, Skh1, Wis1, and Spm1. The
activity of each kinase was assayed after
preincubation with 25 mM (lane 2 in all gels)
or 250 mM (lane 3 in all gels) HWY 5069.
The same amount of each purified kinase
was used in each assay, as shown by the
Western blot of Wis1 at the bottom.
(D) The effect of HWY 5069 on Spc1 with its
physiological substrate. The autophosphory-
lation kinase activity of Spc1 or Wis1 was as-
sayed after preincubation with 10, 25, 100,
and 250 mM HWY 5069. Autophosphorylated
Spc1 or Wis1 was detected by PhosphorIm-
ager analysis.activity of Wis1 (Figure 4D). Altogether, these results
show that HWY 5069 selectively inhibits the kinase
activity of Spc1 on both physiological and general
substrates.
The Mode of Inhibition of Spc1 by HWY 5069
We tested whether the inhibition of Spc1 activity by
HWY 5069 is reversible, as is its effect on cell prolifera-
tion. Figure 5A shows that inhibition of Spc1 activity by
25 mM HWY 5069 was completely reversed by washes
in buffers containing 50 mM or higher concentrations
of NaCl, suggesting that the binding of HWY 5069 to
Spc1 is relatively weak and no doubt involves noncova-
lent interactions.
To characterize the mechanism of Spc1 inhibition by
HWY 5069, we examined whether HWY 5069 competes
with the substrate or ATP for binding to the kinase. In
this experiment, a constant amount of Spc1 was prein-
cubated with MBP or ATP before various concentrations
of HWY 5069 were added. Inhibition was not affected by
preincubation of Spc1 with ATP (Figure 5B), but it was
antagonized by MBP (Figure 5C). Full activity of Spc1
was restored by preincubation with 55 mM MBP
(Figure 5C). These observations demonstrate that HWY
5069 competes with the substrate for binding to Spc1
or at least blocks the access of the substrate to its
binding site.
We analyzed the kinetics of the inhibition by quantify-
ing kinase activity with a PhosphorImager (Figure 5C,table) and plotting relative kinase activities at different
substrate concentrations as a double-reciprocal Line-
weaver-Burke plot based on Michaelis-Menten kinetics
(Figure 5D). The intercept of the plot of 1/relative activity
versus 1/[S] was the same in the presence and absence
of HWY 5069; only the slope increased with increasing
concentrations of HWY 5069 (Figure 5D). This is a typical
plot for competitive inhibitors against the substrate for
binding, and it differs from the mode of action of many
other kinase inhibitors, which are noncompetitive or
bind to the ATP binding site [9, 28, 32, 33].
The Physiological Effect of Spc1 Kinase Activity by
HWY 5069
Thus far, we showed that HWY 5069 blocks the prolifer-
ation of wild-type and other mutants of S. pombe, ex-
cept for the spc1 deletion mutant that is viable. We
also demonstrated that HWY 5069 directly binds to
Spc1 and specifically inhibits its kinase activity. As we
assumed in the rationale of our binding target screen
(Figure 2), these observations strongly suggest that
HWY 5069 does not show cytotoxicity by simply inhibit-
ing Spc1 kinase activity, and that the complex of HWY
5069 and Spc1 is likely to recruit another physiological
target protein required for the viability of S. pombe. To
support this possibility, we generated the kinase-dead
Spc1 mutant by site-directed mutagenesis (Figures 6A
and 6B) and examined whether this kinase-dead mutant
Spc1 can function as a binding target of HWY 5069 and
An Isoquinolinium Derivative Blocks Spc1
885Figure 5. HWY 5069 Binding to Spc1 Is
Reversible and Competes with the Protein
Substrate
(A–C) The same amount of Spc1 was used in
each assay, as shown by Coomassie stain-
ing in (A) and Western blotting in (B). (A) Re-
versibility of HWY 5069 binding. Purified
GST-Spc1 kinase was preincubated with 25
mM HWY 5069, washed three times with
kinase buffer containing 0–100 mM NaCl
(lanes 2–8), and assayed. Lane 1 represents
Spc1 kinase activity without exposure to
HWY 5069. (B and C) The ability of (B) ATP
or (C) MBP to compete with HWY 5069 for
binding to Spc1 kinase. Prior to assay, puri-
fied Spc1 kinase was preincubated with ei-
ther (B) ATP or (C) MBP. In (B), kinase activ-
ity was assayed in the presence of 25 mM
HWY 5069 or DMSO. In (C), activity was
assayed with increasing concentrations of
HWY 5069 (0, 8, 16.4, and 20 mM from top
to bottom). Each relative kinase activity
was calculated in comparison with HWY
5069-untreated activity based on the inten-
sity obtained by PhosphorImager and is
shown at the bottom of the table.
(D) Lineweaver-Burke plots of the kinase ac-
tivity as a function of substrate concentra-
tion and different amounts of HWY 5069.
The Microexcel program was used for analy-
sis.induce cytotoxicity (Figure 6C). As shown in Figure 6C,
HWY 5069 completely inhibited the proliferation of
both the cells expressing wild-type or the kinase-dead
Spc1. This result demonstrates that although HWY
5069 specifically inhibits the kinase activity of Spc1,
the inhibition of its kinase activity is not the cause of
the cytotoxicity of HWY 5069, and it strongly advocates
the presence of a critical physiological target recruited
as assumed in the screen (Figure 2).
The Effects of HWY 5069 on Stress-Activated
Mammalian MAPKs
Given that the stress-activated MKK4/7-JNK/SAPK and
MKK3/6-p38 pathways of mammals and the Wis1-Spc1
pathway of fission yeast [15, 19] are highly conserved,
we asked whether HWY 5069 can inhibit the MAPKs
JNK and p38. We also examined the inhibitory effect of
HWY 5069 on ERK, since the MAPKs ERK, p38, and
JNK contain a conserved common docking motif for
their interactions with substrates and regulators [34].
We isolated JNK, p38, and ERK from two different cell
lines, CHO and HEK 293, to ensure the cell type-inde-
pendent effect of HWY 5069 on these kinases. Cells of
each cell line were activated by osmotic stress, and
JNK, p38, and ERK were immunoprecipitated and as-
sayed after preincubation with HWY 5069. Their kinase
activities were not at all inhibited, even with 250 mM
HWY 5069 (Figure 7A), whereas SB203580 and
SP600125, the commercially available mammalian
MAPK inhibitors, completely inhibited p38 and JNK, re-
spectively, and PD98059 partially blocked the activity of
ERK1/2 (Figure 7A).Because HWY 5069 appears to bind to the substrate
binding domain of Spc1 and because MAPKKs also
hold the specific docking domains (D domains) that
partly achieve the substrate specificity of MAPKs [34],
we tested whether HWY 5069 inhibits several activated
mammalian MAPKKs—MEK1, MKK4, and MKK3/6.
HWY 5069 failed to inhibit these kinases, whereas the
mammalian MEK1/2-specific inhibitor U0126 com-
pletely blocked MEK1 activity. Since no specific inhibi-
tors are available for MKK3/6 and MKK4, we used
U0126 as a control inhibitor for MKK3/6 and MKK4 (Fig-
ure 7B). However, even up to 250 mM U0126 only slightly
inhibited the kinase activity of MKK3 and MKK4 both
in HEK 293 and CHO cells (Figure S1; see the Supple-
mental Data available with this article online). Taken
together, these observations indicate that HWY 5069
acts very selectively on the stress-activated MAPK
Spc1 of S. pombe.
Discussion
In light of our previous observation that two berberine
derivatives, HWY 336 and HWY 289, specifically in-
hibited the MAPKK Wis1 of S. pombe [28], we extended
the search for selective inhibitors of the kinases of
MAPK cascades by synthesizing various derivatives of
one of the isoquinoline rings of the protoberberine back-
bone. The target kinases of 80 modified isoquinolinium
derivatives were investigated by comparing their inhibi-
tory effect on wild-type fission yeast cells and on various
kinase mutants. One of the isoquinolinium derivatives,
HWY 5069, inhibited the growth of wild-type S. pombe
Chemistry & Biology
886and all examined mutants, except for a strain lacking
Spc1. In vitro kinase assays with purified MAPK cascade
components confirmed that HWY 5069 specifically in-
hibits Spc1. Thus, the kinase inhibition by isoquinoli-
nium derivatives appears to be highly specific and to
depend on the type of modification made.
HWY 5069 blocks Spc1 activity by competing with
substrate, suggesting that it may bind to or modify the
substrate binding site of Spc1. To understand the struc-
tural basis of the selectivity of HWY 5069, we have com-
pared the predicted three-dimensional structures of
Figure 6. Inhibition of the Proliferation of S. pombe by HWY 5069
Depends on the Presence of Spc1 Kinase, but Not on Its Kinase
Activity
(A) The kinase-dead Spc1 was produced by switching threonine
171 to alanine and tyrosine 173 to phenylalanine as described in
Experimental Procedures.
(B) Wild-type and GST-spc1-KD in pREP1 were respectively ex-
pressed in spc1D and purified as shown by the Western blot with
anti-GST antibodies. The kinase-dead Spc1 (KD-Spc1) was verified
by comparing its MBP phosphorylation with wild-type Spc1.
(C) The effect of HWY 5069 on cell proliferation was compared in
cells expressing wild-type Spc1 (spc1D transformed with GST-
spc1 in pREP1), KD-Spc1 (spc1D transformed with GST-spc1-KD
in pREP1), and no Spc1 (spc1D transformed with pREP1 vector
only). The expression from the pREP1 nmt1 promoter was main-
tained at its basal level by incubating the cells in the presence of
0.04 mM thiamine at 29C [51]. The same number of S. pombe cells
in early-log phase was incubated for 30 hr with 3.76 mM HWY 5069
and DMSO (solvent) as a negative control.
All experiments were performed three times, and averages with
standard deviations are plotted.several kinases in S. pombe MAPK cascades, namely,
Wis1, Win1, Spc1, and Spm1 (data not shown) [28]. Their
structures are fairly conserved, except for the size of an
extended pocket near their peptide binding sites [35].
The degree of the openness of the pocket is thought
to be responsible for the inhibitor selectivity of the differ-
ent MAP kinases [36]. The structure of Spc1 suggests
that it may contain a larger pocket at its substrate bind-
ing site than Wis1, and this may be responsible for the
weak binding and the specificity of HWY 5069 for
Spc1. Further investigation of the interaction between
HWY 5069 and Spc1 kinase may suggest ways of mod-
ifying isoquinolinium derivatives to obtain other selec-
tive kinase inhibitors. Given that the specificity of the
available protein kinase inhibitors targeting the ATP
binding site tends to be rather low, the competitive bind-
ing of HWY 5069 to Spc1 with specific substrate is of
considerable interest [27, 32].
HWY 5069 was identified because it inhibited the pro-
liferation of wild-type S. pombe and all mutants, except
for spc1D, and selectively blocked Spc1 activity in vitro.
Considering that the deletion of Spc1 is not lethal and
that HWY 5069 blocks proliferation of the cells express-
ing the kinase-dead Spc1, inhibition of S. pombe prolif-
eration by HWY 5069 is not simply due to the inhibition
of Spc1 kinase activity. As illustrated in Figure 2, the
binding of HWY 5069 to Spc1 may recruit (and trap)
other essential molecules required for the proliferation
of S. pombe. This possibility is further supported by
the report that Spc1 is involved in cell cycle control
[37, 38]. For example, regardless of its kinase activity,
Spc1 interacts with Cdc37, an evolutionally conserved
kinase-specific chaperone, which has been shown to
maintain cellular viability and multiple cell cycle func-
tions [39–41]. Cdc37 also associates with the catalytic
domain of a MAPK kinase, MLK3 (mixed-lineage kinase
3), independently of its kinase activity in mammalian
cells [42]. Turnbull et al. recently showed that Cdc37
of S. pombe regulates the activity of the mitotic kinase
Cdc2 and its interaction with the cyclin Cdc13 [43].
These reports support our model showing that HWY
5069 binds to Spc1 at its substrate binding domain
independently of its kinase activity, and that it affects
the interaction of Spc1 with a protein that is critical
for cell cycle control, such as Cdc37, to block cell
proliferation.
In addition, recent studies have shown that the dock-
ing of MAPKs via the common docking domain (the CD
domain) and the docking groove separate from the CD
determines their selectivity for interactions with sub-
strates and scaffold proteins [44–46]. Therefore, it is
also conceivable that the binding of HWY 5069 to the
substrate binding domain of Spc1 may cause a struc-
tural change in the docking domains to enhance the
interaction with physiological target protein(s).
The stress-activated Wis1-Spc1 MAP kinase pathway
is highly conserved and is homologous to the stress-ac-
tivated MKK4/7-JNK/SAPK and MKK3/6-p38 cascades
in mammalian cells [1, 2, 19]. Since HWY 5069 selec-
tively inhibits Spc1, we expected that it would also in-
hibit JNK/SAPK and/or p38. Remarkably, however, it
failed to block these mammalian MAPKs. Moreover,
based on the result that HWY 5069 selectively binds to
the substrate binding domain of Spc1, we assessed
An Isoquinolinium Derivative Blocks Spc1
887Figure 7. HWY 5069 Does Not Inhibit Mam-
malian Stress-Activated MAPK Kinases
Such as the Spc1 Homologs p38 and JNK
(A and B) (A) p38, JNK, and ERK1/2 and (B)
MEK1, MKK3/6, and MKK4 were immuno-
precipitated from HEK 293 and CHO cells af-
ter activation as described in Experimental
Procedures. The activity of each immuno-
precipitated kinase was assayed with MBP
as a substrate (denoted as K/A) after pre-
treatment with 25 mM HWY 5069 (lanes 2),
250 mM HWY 5069 (lanes 3), DMSO (lanes
1), and a known inhibitor of each kinase (25
or 250 mM U0126, 250 mM PD98059, 25 mM
SB203580 and SP600125) as positive con-
trols (lanes 4). A similar amount of each ki-
nase was used in each assay, as shown by
the immunoblots with each antibody at the
bottom.the effect of HWY 5069 on the activated mammalian
MAPKKs—MEK1, MKK4, and MKK3/6—because
MAPKKs also contain the specific docking domains (D
domains) proven to contribute the substrate specificity
of MAPKs [34]. However, HWY 5069 failed to inhibit the
activities of mammalian MAPKKs. This high specificity
of HWY 5069 again suggests that other isoquinolinium
derivatives with further modifications might prove to
be specific for other kinases in the MAPK cascades of
yeast and mammals. In addition, the selectivity of HWY
5069 for a yeast MAPK indicates that it may be useful
as an antifungal agent. Examination of the effect of
HWY 5069 on the proliferation of fungal pathogens
such asCandidawill be needed to evaluate this possibil-
ity, as Candida also has a conserved stress-activated
MAPK cascade and an Spc1 homolog.
Significance
MAPK cascades are highly conserved signaling cas-
settes in all eukaryotes that regulate proliferation,
differentiation, inflammation, and cell death. Several
MAPK cascades exist in a cell, each of which trans-
duces a specific signal and also interacts with others
to form a complex network. Thus, how the specificity
of eachMAPKpathway ismaintained is a key question,
and its investigation has been aided by the develop-
ment of a number of synthetic compounds against
specific components of the cascades. In addition,
since the MAPK cascades are deeply involved in the
processes of fungal growth and oncogenic and inflam-
matory signaling, inhibitors of particular kinases in the
MAPK pathways are candidates for cytotoxic antifun-
gal, antitumor, or anti-inflammatory drugs. Therefore,
many efforts have been put into developing selective
inhibitors of the MAPK pathways. In this study, we
suggest a genetic approach to use various kinase
knockout mutants of the MAPK cascades in identify-
ing compounds that selectively bind to these kinases,
since deletion of the components inMAPKcascades isgenerally not lethal. By comparing the effect of chem-
ical compounds to the growth of wild-type and each
knockout mutant, we were able to screen a target-ori-
entated library of isoquinolinium derivatives to isolate
compounds that at least employ these kinases as
binding targets. One identified compound was HWY
5069, which binds to and selectively inhibits one spe-
cific kinase of the MAPK cascades, Spc1, by compet-
ing with the substrate for binding to the enzyme. Its
high selectivity and competition with substrate sug-
gest that further modifications of isoquinolinium
derivatives may provide selective inhibitors of other
kinases. Moreover, the selectivity of HWY 5069 for
a fungal MAPK suggests that it could be developed
into a potent antifungal agent.
Experimental Procedures
Abbreviations Used
Abbreviations used in this article are as follows: S. pombe, Schizo-
saccharomyces pombe; MAPK, mitogen-activated protein kinase,
sometimes referred to as ERK; ERK, extracellular signal-regulated
kinase; MEK, MAPK/ERK kinase, sometimes referred to as MKK or
MAPKK; MAPKKK, MAPK/ERK kinase kinase, sometimes referred
to as MEKK; JNK, c-Jun N-terminal kinase; SAPK, stress-activated
protein kinase; MBP, myelin basic protein; DMSO, dimethyl sulfox-
ide; MIC, minimal inhibitory concentration; IC50, a concentration
for 50% inhibition; GST, glutathione S-transferase; CHO cell, Chi-
nese hamster ovary cell; HEK 293 cell, human embryonic kidney
293 cell.
Synthesis of the Modified Isoquinoline Derivative HWY 5069
HWY 5069 (3, 4-dihydro-2-[4-(2,2-dimentylethyl)benzyl]-6-fluoro-1-
undacanylisoquinolinium bromide) was synthesized as illustrated
in Figure 1B, from a phenylethylamine derivative (Sigma) that repre-
sents half of the backbone of protoberberine (Figure 1A). The struc-
ture of HWY 5069 was verified by 1H NMR (300 MHz, CDCl3),
13C
NMR (75 MHz, CDCl3), and HR-MS spectroscopic analyses:
1H
NMR (300 MHz, CDCl3) d 7.98 (dd, J = 9.0, 2.4Hz, 1H), 7.47 (d, J =
8.4Hz, 2H), 7.31(d, J = 8.4Hz, 2H), 7.21 (ddd, J = 9.0, 8.4, 2.4Hz,
1H), 7.10 (dd, J = 8.4, 2.4Hz, 1H), 5.59 (s, 2H), 4.19 (m, 2H), 3.35 (m,
4H), 1.73 (m, 6H), 1.52 (m, 2H), 1.33 (s, 9H), 1.25 (m, 10H), 0.89 (t,
J = 6.6Hz, 3H); 13C NMR (75. MHz, CDCl3) d 178.61, 169.14, 165.64,
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888152.94, 141.71, 141.58, 133.92, 133.77, 128.68, 127.88, 126.74,
123.32, 116.47, 116.35, 116.17, 116.06, 60.90, 51.15, 34.86, 32.54,
31.95, 31.31, 30.01, 29.62, 29.59, 29.44, 29.37, 29.14, 28.98, 26.66,
22.75, 14.19; HR-MS (FAB) (m/z) found 450.3536 [M-Br]+, calculated
for C31H45FN 450.3536.
Growth of S. pombe and Inhibition by HWY 5069
The S. pombe strains used in this study are as listed: KGY246 (h2
leu1-32 ura4-d18 ade6-M210), SPSU (h90 leu1-32 ura4-d18 ade6-
M210 byr2::ura4+), SPBU (h90 leu1-32 ura4-d18 ade6-M210 by-
r1::ura4+), JM544 (h2 leu1-32 wis1::ura4+), KS1366 (h2 leu1-32
spc1::ura4+), ED1388 (h2 leu1-32 ura4-d18 ade6-M216 win1::ura4+),
ED1217 (h2 leu1-32 ura4-d18 his1-102 wis4::ura4+), TZs69 (h2 leu1-
32 ura4-d18 spm1::LEU2), RL142 (h+ leu1-32 ura4-d18 ade6-M210
skh1::ura4+), AS1-11b (h+ leu1-32 ura4-d18 ade6-M210
mkh1::ura4+), KGY19 (h2 cdc2-33 leu1-32), YDM114 (h+ plo1-24C
leu1-32 ura4-d18 ade6-M210). They were grown in yeast extract
(YE) or minimal medium (MM) with supplements of 0.75 mg/l ade-
nine, uracil, and leucine and 0.4 mM thiamine, as required [47]. Cells
were transformed with lithium acetate [48].
A stock solution of HWY 5069 (1 mg/ml) was prepared in DMSO.
The MIC of HWY 5069 for wild-type S. pombe was determined by
transferring cells in mid-log phase (53 106 cells/ml) into a fresh me-
dium containing different concentrations of HWY 5069. Cells were
incubated with shaking and were counted every 3 hr for 24 hr to
monitor growth rate. DMSO had no visible effect on cell growth.
Purification of S. pombe Protein Kinases
and an Assay of Kinase Activity
Wild-type S. pombe (KGY246) cells were transformed with plasmids
encoding 6XHis/HA-tagged Win1, Skh1, Spm1, and Byr1 or plas-
mids encoding GST-tagged Wis1 or Spc1; cells were grown to
mid-log phase. Expression from the pREP1 nmt1 promoter was in-
duced by incubating the cells in the absence of thiamine for 18 hr
at 29C [49]. Before harvesting, cells expressing tagged Win1,
Skh1, Spm1, Wis1, or Spc1 were exposed to 0.6 M KCl for 20 min
to activate the kinases by osmotic stress, and cells expressing
Byr1 were incubated in nitrogen-free medium for 6 hr to activate
that kinase by nitrogen starvation. The kinases were purified as de-
scribed in Jang et al. [28]. Protein was measured with the Bradford
dye binding assay (Bio-Rad), and each kinase assay was performed
with approximately the same amount of kinase in a buffer (25 mM
HEPES [pH 7.5], 60 mM b-glycerophosphate, 15 mM EGTA, 0.1
mM Na-orthovanadate, 0.1% Triton X-100, 1 mM PMSF) with 1
mg/ml MBP (Sigma), 1 mM ATP and 20 mCi [g-32P]ATP for 30 min
at 30C. MBP was then resolved on 12.5% SDS-PAGE gels, auto-
radiographed, and quantified with a PhosphorImager (BAS-2500,
FUJI). Reversibility of the inhibitory action of HWY 5069 on Spc1 ac-
tivity was determined by washing 25 mM HWY 5069-treated Spc1 ki-
nase with kinase buffer containing a range of NaCl concentrations
(from 0 to 100 mM) prior to kinase assays.
Site-Directed Mutagenesis of Spc1
A kinase-dead Spc1 was produced essentially by following the
procedure described by Fre´de´rique et al. [50]. spc1 in pREP1 was
amplified by PCR with the oligonucleotides 50-CCTCAAATG
GCTGGCTTCGTTTCTACTCG-30 and 50-CGAGTAGAAACGAAGC
CAGCCATTTGAGG-30 that hold mutations in the sequences (95C
30 s, 50C 1 min, 68C 20 min). The underlined sequences indicate
the mutated codons. The PCR-mutagenized spc1 in pREP1 was
saved by Dpn1 digestion, analyzed by electrophoresis, and con-
firmed by DNA sequencing and kinase assay.
Mammalian Cell Culture and Assays of Kinases
in Mammalian MAP Kinase Cascades
HEK 293 cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) (GIBCO-BRL), and CHO cells were cultured in F12 Nutrient
mixture medium (GIBCO-BRL), each with 10% fetal bovine serum
(FBS) (GIBCO-BRL) and 1% antibiotics (penicillin-streptomycin)
(GIBCO-BRL). Cells detached from flasks with 0.25% trypsin-
EDTA (GIBCO-BRL) were adjusted to 104 cells/ml, cultured in a
140 mm plate for 2 days, and harvested. Kinases in the stress-acti-
vated MAPK cascades were activated prior to harvest by serum
starvation for 12 hr and/or by the addition of 600 mM sorbitol for15 min. A total of 500 ml of each lysate was incubated overnight
with the appropriate kinase antibody (MEK1, Upstate; MKK3/6,
MKK4, ERK1, p38, JNK, Cell Signaling and New England Biolabs)
(1:150), followed by 60 ml protein A-Sepharose and protein A-aga-
rose (Sigma) for 90 min at 4C. The immunopurification of each
kinase was confirmed by Coomassie staining or Western blot-
ting. Each purified kinase was exposed to HWY 5069, U0126,
SB203580, SP600125, PD98059, or DMSO for 20 min at 30C in a ki-
nase buffer (25 mM Tris [pH 7.5], 5 mM b-glycerolphosphate, 2 mM
DTT, 0.1 mM Na3VO4, 10 mM MgCl2, 1 mM PMSF) and was assayed
by adding 1 mg/ml MBP (Sigma), 1 mM ATP, and 10 mCi [g-32P]ATP
for 30 min.
Supplemental Data
Supplemental Data include the kinase assay of MKK3 and MKK4
with various concentrations of U0126 to show that U0126 is not
a specific inhibitor against MKK3 and MKK4 even though we used
it as a control, since no specific inhibitors are available for MKK3
and MKK4. This information is available at http://www.chembiol.
com/cgi/content/full/13/8/881/DC1/.
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